Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Thu, 27.04.2023
Formycon AG
Press Release // April 27, 2023
Formycon publishes results for financial year 2022
Approval and commercial launch of FYB201 as well as ATHOS transaction mark transformative fiscal year
Group revenues increase to Euro 42.5 million (2021 IFRS: Euro 36.6 million) and include first earning contributions from commercialization of FYB201
EBITDA of Eu [ … ]
Tue, 25.04.2023
Formycon AG
Press Release // April 25, 2023
Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Positive data from extended Phase I pharmacokinetics study complete clinical development program
Phase I and phase III clinical trial program demonstrated comparable safety [ … ]
Tue, 25.04.2023
Formycon AG
Press Release // April 25, 2023
Formycon announces successful results of Phase I clinical trial for ustekinumab biosimilar candidate FYB202 and concludes clinical development
Positive data from extended Phase I pharmacokinetics study complete clinical development program
Phase I and phase III clinical trial program demonstrated comparable safety [ … ]
Tue, 07.02.2023
Formycon AG
Press Release // February 7, 2023
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Munich, Germany - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
[ … ]
Tue, 07.02.2023
Formycon AG
Press Release // February 7, 2023
Enno Spillner appointed Chief Financial Officer (CFO) of Formycon AG
Munich, Germany - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) today announced that the Company's Supervisory Board has appointed Mr. Enno Spillner to the Company's Executive Board as Chief Financial Officer (CFO) effective April 1, 2023.
[ … ]
Mon, 06.02.2023
Formycon AG
Press Release // February 6, 2023
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
MAGELLAN-AMD study demonstrates the comparable efficacy of FYB203 to the reference product Eylea® in patients with neovascular age-related macular degeneration (nAMD)
Primary efficacy endpoint fo [ … ]
Mon, 06.02.2023
Formycon AG
Press Release // February 6, 2023
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
MAGELLAN-AMD study demonstrates the comparable efficacy of FYB203 to the reference product Eylea® in patients with neovascular age-related macular degeneration (nAMD)
Primary efficacy endpoint fo [ … ]
Thu, 02.02.2023
Formycon AG
Press Release February 2, 2023
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced [ … ]
Thu, 02.02.2023
Formycon AG
Press Release February 2, 2023
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), as the exclusive owner of the global commercial rights to FYB202, a biosimilar candidate to Stelara® (ustekinumab), announced [ … ]
Thu, 02.02.2023
Formycon AG
NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION, PUBLICATION OR TRANSMISSION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PUBLICATION.Publication of ins [ … ]